Targeted PLGA–Chitosan Nanoparticles for NIR-Triggered Phototherapy and Imaging of HER2-Positive Tumors

Targeted PLGA–Chitosan Nanoparticles for NIR-Triggered Phototherapy and Imaging of HER2-Positive Tumors

Targeted medicine uses the distinctive features of cancer cells to find and destroy tumors. We present human epidermal growth factor receptor 2 (HER2)-targeted PLGA–chitosan nanoparticles for cancer therapy and visualization. Loading with two near-infrared (NIR) dyes provides imaging in the NIR tran...

Full description

Bibliographic Details
Main Authors:	Polina A. Kotelnikova, Victoria O. Shipunova, Sergey M. Deyev
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Pharmaceutics
Subjects:	PLGA HER2 trastuzumab photodynamic therapy IR-780 Nile Blue
Online Access:	https://www.mdpi.com/1999-4923/16/1/9

Similar Items

PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death
by: Victoria Olegovna Shipunova, et al.
Published: (2021-06-01)

Mitochondria-Targeting Oxygen-Sufficient Perfluorocarbon Nanoparticles for Imaging-Guided Tumor Phototherapy
by: Chen S, et al.
Published: (2020-11-01)

Targeted Two-Step Delivery of Oncotheranostic Nano-PLGA for HER2-Positive Tumor Imaging and Therapy In Vivo: Improved Effectiveness Compared to One-Step Strategy
by: Victoria O. Shipunova, et al.
Published: (2023-03-01)

Two-Step Targeted Drug Delivery via Proteinaceous Barnase-Barstar Interface and Doxorubicin-Loaded Nano-PLGA Outperforms One-Step Strategy for Targeted Delivery to HER2-Overexpressing Cells
by: Elena N. Komedchikova, et al.
Published: (2022-12-01)

Preparation of NIR-sensitive, photothermal and photodynamic multi-functional Mxene nanosheets for laryngeal cancer therapy by regulating mitochondrial apoptosis
by: Yiyi Lin, et al.
Published: (2022-08-01)

Association of Indocyanine Green with Chitosan Oleate Coated PLGA Nanoparticles for Photodynamic Therapy
by: Dalila Miele, et al.
Published: (2022-08-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells
by: Caputo TM, et al.
Published: (2023-11-01)

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics
by: Phuong-Thao Dang-Luong, et al.
Published: (2024-02-01)

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗
by: Erica L. Mayer, MD, MPH
Published: (2020-06-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
by: Liu Yang, et al.
Published: (2022-04-01)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
by: Baubek Spanov, et al.
Published: (2022-01-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

HER2 expression, gene amplification and chromosome 17 copy number in primary pancreatic adenocarcinoma, matastatic lymph node and metastasis
by: S. Boccardo, et al.
Published: (2011-01-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice
by: Maria Bonomi, et al.
Published: (2024-03-01)

Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses
by: Ma B, et al.
Published: (2019-06-01)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
by: Paul Stewart, et al.
Published: (2020-12-01)

Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
by: Jeffrey V. Leyton
Published: (2020-07-01)

The Exciting New Field of HER2-Low Breast Cancer Treatment
by: Daniel Eiger, et al.
Published: (2021-03-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
by: Li Wang, et al.
Published: (2022-01-01)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
by: Yoshiya Horimoto, et al.
Published: (2022-03-01)

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
by: Ioannis A. Vathiotis, et al.
Published: (2021-12-01)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
by: Shirman Y, et al.
Published: (2023-08-01)

Dye-loaded mesoporous polydopamine nanoparticles for multimodal tumor theranostics with enhanced immunogenic cell death
by: Ying Tian, et al.
Published: (2021-11-01)

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
by: Caroline Fong, et al.
Published: (2022-08-01)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance
by: Gerjon J. Ikink, et al.
Published: (2017-03-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies
by: Hongmei Xiao, et al.
Published: (2019-09-01)